NovoCure Limited (NVCR)

NovoCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	642.27	605.22	509.34	537.84	535.03	494.37
Revenue Growth (YoY)	11.17%	18.82%	-5.30%	0.53%	8.23%	40.72%
Cost of Revenue	157.18	136.18	127.54	114.26	114.24	106.09
Gross Profit	485.09	469.05	381.8	423.58	420.79	388.27
Selling, General & Admin	444.27	427.21	386.97	306.41	263.18	225.45
Research & Development	214.57	209.37	220.99	206.09	201.3	132.01
Operating Expenses	658.84	636.58	607.96	512.5	464.49	357.46
Operating Income	-173.75	-167.54	-226.16	-88.91	-43.69	30.81
Interest Expense	-13.67	-10.34	-3.32	-3.33	-3.44	-17.58
Interest & Investment Income	14.07	22.72	19.64	10.96	0.79	1.79
Currency Exchange Gain (Loss)	-0.72	-0.72	-0.8	-3.52	-4.03	2.65
Other Non Operating Income (Expenses)	-0.6	-0.6	-0.79	-1.26	-1.37	-0.47
EBT Excluding Unusual Items	-174.68	-156.48	-211.42	-86.06	-51.74	17.2
Merger & Restructuring Charges	-2	-2	-6.23	-	-	-
Gain (Loss) on Sale of Investments	28.27	28.27	26.4	4.83	0.31	1.32
Asset Writedown	-0.95	-0.95	-0.48	-0.61	-0.64	-0.41
Other Unusual Items	-1.14	-	-	-	-	-
Pretax Income	-150.5	-131.16	-191.74	-81.85	-52.08	18.1
Income Tax Expense	27.15	37.47	15.3	10.69	6.28	-1.71
Net Income	-177.65	-168.63	-207.04	-92.53	-58.35	19.81
Net Income to Common	-177.65	-168.63	-207.04	-92.53	-58.35	19.81
Shares Outstanding (Basic)	111	108	106	105	103	101
Shares Outstanding (Diluted)	111	108	106	105	103	109
Shares Change (YoY)	2.82%	1.36%	1.65%	1.19%	-5.00%	11.97%
EPS (Basic)	-1.61	-1.56	-1.95	-0.88	-0.56	0.20
EPS (Diluted)	-1.61	-1.56	-1.95	-0.88	-0.56	0.18
Free Cash Flow	-65.17	-69.22	-100.43	9.43	58.59	84.18
Free Cash Flow Per Share	-0.59	-0.64	-0.94	0.09	0.57	0.77
Gross Margin	75.53%	77.50%	74.96%	78.76%	78.65%	78.54%
Operating Margin	-27.05%	-27.68%	-44.40%	-16.53%	-8.17%	6.23%
Profit Margin	-27.66%	-27.86%	-40.65%	-17.21%	-10.91%	4.01%
Free Cash Flow Margin	-10.15%	-11.44%	-19.72%	1.75%	10.95%	17.03%
EBITDA	-161.59	-157.67	-216.46	-79.34	-34.53	38.56
EBITDA Margin	-25.16%	-26.05%	-42.50%	-14.75%	-6.45%	7.80%
D&A For EBITDA	12.17	9.87	9.7	9.57	9.17	7.75
EBIT	-173.75	-167.54	-226.16	-88.91	-43.69	30.81
EBIT Margin	-27.05%	-27.68%	-44.40%	-16.53%	-8.17%	6.23%

Updated Oct 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q